In Brief: Sanofi Plavix
Executive Summary
Sanofi Plavix: FDA's Cardiovascular & Renal Drugs Advisory Committee will review NDA (20-839) for Plavix (clopidogrel) for prevention of vascular ischemic events in patients with a history of symptomatic atherosclerosis on Oct. 24. On Oct. 23, committee will consider Ohmeda's nitric oxide NDA (20-845) for treatment of primary pulmonary hypertension in newborns. The meeting will be held at the NIH's Masur auditorium beginning at 8:30...